These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23486268)

  • 21. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
    Cornelissen R; Lievense LA; Robertus JL; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
    Lung Cancer; 2015 Jun; 88(3):332-7. PubMed ID: 25843042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
    Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Christoph DC; Asuncion BR; Mascaux C; Tran C; Lu X; Wynes MW; Gauler TC; Wohlschlaeger J; Theegarten D; Neumann V; Hepp R; Welter S; Stamatis G; Tannapfel A; Schuler M; Eberhardt WE; Hirsch FR
    J Thorac Oncol; 2012 Sep; 7(9):1440-8. PubMed ID: 22895141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
    Armato SG; Nowak AK
    J Thorac Oncol; 2018 Jul; 13(7):1012-1021. PubMed ID: 29753121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
    Reck M; Heigener DF; Gatzemeier U
    Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
    Gudmundsson E; Labby Z; Straus CM; Sensakovic WF; Li F; Rose B; Cunliffe A; Kindler HL; Armato SG
    Eur Radiol; 2019 Feb; 29(2):682-688. PubMed ID: 29967955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
    Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
    Paajanen J; Laaksonen S; Ilonen I; Wolff H; Husgafvel-Pursiainen K; Kuosma E; Ollila H; Myllärniemi M; Vehmas T
    Lung Cancer; 2018 Feb; 116():73-79. PubMed ID: 29413055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
    Papa S; Popat S; Shah R; Prevost AT; Lal R; McLennan B; Cane P; Lang-Lazdunski L; Viney Z; Dunn JT; Barrington S; Landau D; Spicer J
    J Thorac Oncol; 2013 Jun; 8(6):783-7. PubMed ID: 23571475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deciduoid pleural mesothelioma in an adolescent.
    Arango-Tomás E; Algar-Algar FJ; Salvatierra Velázquez A
    Arch Bronconeumol; 2013 May; 49(5):218-9. PubMed ID: 23265622
    [No Abstract]   [Full Text] [Related]  

  • 33. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
    Baldini EH; Richards WG; Gill RR; Goodman BM; Winfrey OK; Eisen HM; Mak RH; Chen AB; Kozono DE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2015 May; 149(5):1374-81. PubMed ID: 25772281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.
    Hashimoto M; Takeuchi J; Takuwa T; Kuroda A; Nakamura A; Nakamichi T; Matsumoto S; Kondo N; Nakano T; Morimoto T; Hasegawa S
    J Thorac Cardiovasc Surg; 2019 Jan; 157(1):404-413. PubMed ID: 30557956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
    Raphael J; Le Teuff G; Hollebecque A; Massard C; Bahleda R; Margery J; Besse B; Soria JC; Planchard D
    Lung Cancer; 2014 Aug; 85(2):251-7. PubMed ID: 24882384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
    Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
    Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
    J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
    Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
    Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.